Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 2
1967 3
1968 2
1969 1
1976 1
1997 2
2001 1
2002 2
2003 1
2004 3
2005 1
2006 1
2009 1
2010 1
2011 2
2012 2
2013 2
2014 2
2015 2
2016 2
2018 2
2019 1
2021 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study.
Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, Albrand G, Servent V, Jean OS, van Praagh I, Kurtz JE, Périn S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Mathoulin-Pélissier S, Rainfray M. Soubeyran P, et al. Among authors: van praagh i. PLoS One. 2014 Dec 11;9(12):e115060. doi: 10.1371/journal.pone.0115060. eCollection 2014. PLoS One. 2014. PMID: 25503576 Free PMC article. Clinical Trial.
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Passildas-Jahanmohan J, Eymard JC, Pouget M, Kwiatkowski F, Van Praagh I, Savareux L, Atger M, Durando X, Abrial C, Richard D, Ginzac Couvé A, Thivat E, Monange B, Chollet P, Mahammedi H. Passildas-Jahanmohan J, et al. Among authors: van praagh i. Cancer Med. 2021 Apr;10(7):2332-2340. doi: 10.1002/cam4.3806. Epub 2021 Mar 5. Cancer Med. 2021. PMID: 33666378 Free PMC article. Clinical Trial.
Cesarean section for fetal distress.
Van Praagh IG, Tovell HM. Van Praagh IG, et al. Obstet Gynecol. 1968 May;31(5):674-81. doi: 10.1097/00006250-196805000-00013. Obstet Gynecol. 1968. PMID: 5646399 No abstract available.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Nabholtz JM, Chalabi N, Radosevic-Robin N, Dauplat MM, Mouret-Reynier MA, Van Praagh I, Servent V, Jacquin JP, Benmammar KE, Kullab S, Bahadoor MR, Kwiatkowski F, Cayre A, Abrial C, Durando X, Bignon YJ, Chollet P, Penault-Llorca F. Nabholtz JM, et al. Among authors: van praagh i. Int J Cancer. 2016 May 1;138(9):2274-80. doi: 10.1002/ijc.29952. Epub 2015 Dec 28. Int J Cancer. 2016. PMID: 26649807 Clinical Trial.
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy.
Guiu S, Liegard M, Favier L, van Praagh I, Largillier R, Weber B, Coeffic D, Moreau L, Priou F, Campone M, Gligorov J, Vanlemmens L, Trillet-Lenoir V, Arnould L, Coudert B. Guiu S, et al. Among authors: van praagh i. Ann Oncol. 2011 Feb;22(2):321-8. doi: 10.1093/annonc/mdq397. Epub 2010 Aug 6. Ann Oncol. 2011. PMID: 20693300 Free article.
Prospective Study on Body Composition, Energy Balance and Biological Factors Changes in Post-menopausal Women with Breast Cancer Receiving Adjuvant Chemotherapy Including Taxanes.
Gadéa E, Thivat E, Dubray-Longeras P, Arbre M, Van-Praagh I, Mouret-Reynier MA, Herviou P, Dohou J, Ginzac A, Duclos M, Morio B, Durando X. Gadéa E, et al. Among authors: van praagh i. Nutr Cancer. 2018 Oct;70(7):997-1006. doi: 10.1080/01635581.2018.1502330. Epub 2018 Sep 20. Nutr Cancer. 2018. PMID: 30235012
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F. Nabholtz JM, et al. Among authors: van praagh i. Ann Oncol. 2014 Aug;25(8):1570-7. doi: 10.1093/annonc/mdu183. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827135 Free article. Clinical Trial.
35 results